tiprankstipranks
Vivimed Labs Limited (IN:VIVIMEDLAB)
:VIVIMEDLAB
India Market
Want to see IN:VIVIMEDLAB full AI Analyst Report?

Vivimed Labs Limited (VIVIMEDLAB) Price & Analysis

1 Followers

VIVIMEDLAB Stock Chart & Stats

₹4.95
₹0.00(0.00%)
At close: 4:00 PM EDT
₹4.95
₹0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Diversified Product PortfolioA product mix spanning APIs, finished dosages and specialty chemicals provides durable revenue diversification across drug manufacturing inputs and finished medicines. This reduces single-product exposure, enables cross-selling, and supports utilization of manufacturing assets over multiple product cycles.
B2B / Contract-manufacturing ModelA B2B and contract-manufacturing revenue model supports longer-term supply agreements and repeatable revenues versus spot retail sales. Contract manufacturing can produce steadier plant utilization and predictable order pipelines, improving resilience during demand fluctuations.
Domestic And Export Market AccessOperating across domestic and export markets diversifies geographic demand and regulatory exposure. Access to export markets can enable scale, higher-volume contracts and margin recovery opportunities if regulatory approvals are maintained, supporting longer-term commercial stability.
Bears Say
Declining Revenue And Collapsing MarginsSustained revenue decline and a dramatic gross-margin collapse indicate structural loss of pricing power, adverse product mix shifts, or competitive pressure. This erodes cash generation and the ability to fund R&D, capex, or recovery initiatives, making operational turnarounds harder to execute.
Negative Equity And Extreme LeverageNegative shareholder equity and an extreme debt-to-equity ratio signal solvency stress and constrained financial flexibility. This condition raises refinancing and covenant risks, limits ability to raise growth capital, and can force strategic concessions to creditors over long-term value creation.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flows reduce liquidity and necessitate external funding to sustain operations. Persistent cash deficits increase default and dilution risk, limit investment in product development or capacity, and impair the firm's ability to recover competitively over months.

VIVIMEDLAB FAQ

What was Vivimed Labs Limited’s price range in the past 12 months?
Vivimed Labs Limited lowest stock price was ₹4.88 and its highest was ₹27.99 in the past 12 months.
    What is Vivimed Labs Limited’s market cap?
    Vivimed Labs Limited’s market cap is ₹563.81M.
      When is Vivimed Labs Limited’s upcoming earnings report date?
      Vivimed Labs Limited’s upcoming earnings report date is May 29, 2026 which is in 29 days.
        How were Vivimed Labs Limited’s earnings last quarter?
        Vivimed Labs Limited released its earnings results on Mar 13, 2026. The company reported -₹1.996 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.996.
          Is Vivimed Labs Limited overvalued?
          According to Wall Street analysts Vivimed Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Vivimed Labs Limited pay dividends?
            Vivimed Labs Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on Vivimed Labs Limited dividends here
              What is Vivimed Labs Limited’s EPS estimate?
              Vivimed Labs Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Vivimed Labs Limited have?
              Vivimed Labs Limited has 82,913,910 shares outstanding.
                What happened to Vivimed Labs Limited’s price movement after its last earnings report?
                Vivimed Labs Limited reported an EPS of -₹1.996 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.43%.
                  Which hedge fund is a major shareholder of Vivimed Labs Limited?
                  Currently, no hedge funds are holding shares in IN:VIVIMEDLAB
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Vivimed Labs Limited

                    Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.

                    Vivimed Labs Limited (VIVIMEDLAB) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Balaxi Pharmaceuticals Limited
                    Biofil Chemicals & Pharmaceuticals Ltd.
                    Lasa Supergenerics Ltd.
                    Parenteral Drugs (India) Limited
                    Popular Stocks